Case 38-2004: A 40-year-old man with a large tumor of the skull

New England Journal of Medicine

Volumn 351, Issue 25, 2004, Pages 2637-2645

  Richardson, Paul G ^a,c   Kassarjian, Ara ^b,c   Jing, Wen ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PLASMA PROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; BORDERLINE HYPERTENSION; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRANIOPLASTY; CRANIOTOMY; DIFFERENTIAL DIAGNOSIS; ELECTROLYTE BLOOD LEVEL; HUMAN; KIDNEY FUNCTION TEST; LABORATORY TEST; LIVER FUNCTION TEST; MALE; MENINGIOMA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKULL TUMOR; SUPERIOR SAGITTAL SINUS; TUMOR VOLUME; URINALYSIS; BONE TUMOR; BRAIN; CANCER STAGING; CLAVICLE; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOGRAPHY; SKULL;

ADULT; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; BONE NEOPLASMS; BRAIN; CLAVICLE; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE MYELOMA; NEOPLASM STAGING; PARIETAL BONE; SKULL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 10344222939     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcpc049029     Document Type: Article

References (38)

1. Sheporaitis LA, Osborn AG, Smirniotopoulos JG, Clunie DA, Howieson J, D'Agostino AN. Intracranial meningioma. AJNR Am J Neuroradiol 1992;13:29-37.
2. Arana E, Marti-Bonmati L. CT and MR of focal calvarial lesions. AJR Am J Roentgenol 1999;172:1683-8.
3. Resnick D. Diagnosis of bone and joint disorders. 3rd ed. Philadelphia: W.B. Saunders, 1995:2150-62.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Vol. 3 of World Health Organization classification of tumours. Lyon, France: IARC Press, 2001.
5. Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma: treatment results and conversion to myeloma. Cancer 1992;69:1513-7.
6. Miller FR, Lavertu P, Wanamaker JR, Bonafede J, Wood BG. Plasmacytomas of the head and neck. Otolaryngol Head Neck Surg 1998;119:614-8.
7. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
8. Greipp PR San Miguel JF, Durie BG, et al. A new international staging system (ISS) for multiple myeloma (MM) from the International Myeloma Working Group. Blood 2003;102:190a. abstract.
9. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate treatment in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:448-93.
10. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003;9: 2394-9.
11. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
12. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
13. Jagannath S, Durie BGM, Wolf J, et al. Bortezomib (Velcade, formerly PS-341) as first-line therapy in patients with multiple myeloma (MM). Blood 2003;102:236a. abstract.
14. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127-30.
15. Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment Oncology 1984;41:180-4.
16. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341: 1565-71. [Erratum, N Engl J Med 2000;342: 364.]
17. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002;53:629-57.
18. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003;10:375-83.
19. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004;79:875-82.
20. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002;13:1116-9.
21. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98:1614-5.
22. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
23. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
24. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9.
25. Rajkumar SV, Blood E, Vesole DH, Shepard R, Greipp PR. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group. Prog Proc Am Soc Clin Oncol 2004; 23:560. abstract
26. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
27. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
28. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
29. LeBlanc R, Catley LP, HideshimaT, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
30. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase 1 trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
31. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib vs. dexamethasone in relapsed multiple myeloma: a phase 3 randomized study. Prog Proc Am Soc Clin Oncol 2004;23:558. abstract.
32. Cavenagh JD, Curry N, Stec J, et al. PAD therapy (bortezomib, doxorubicin and dexamethasone) for untreated multiple myeloma (MM). Prog Proc Am Soc Clin Oncol 2004;23:570. abstract.
33. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
34. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
35. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502. [Erratum, N EnglJ Med 2004;350:2628.]
36. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54.
37. Attal M. Roundtable on autologous transplantation: the IFM experience. In: Proceedings of the Multiple Myeloma 2004 Conference, Torino, Italy, April 22-24, 2004:111-2. abstract.
38. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37.